Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Al Jalila Children's Specialty Hospital Ink Rapid Whole-Genome Sequencing Deal

NEW YORK – Al Jalila Children's Specialty Hospital, based in Dubai, United Arab Emirates, said on Monday that it has signed a deal with Illumina to collaborate on rapid whole-genome sequencing for diagnosing critically ill children.

Under the terms of the agreement, the partners will collaborate on a two-year study of the impact of clinical rWGS in neonatal and pediatric care units. The study will comprise 200 children under the age of 18 and their parents. Illumina will provide sequencing reagents and analytical tools for rWGS.

Financial and other terms of the deal were not disclosed.

Al Jalila Children's genomic center has received CAP accreditation, the hospital said in a statement.

"We are committed to increasing genomic capability in the UAE," Illumina Chief Commercial Officer Susan Tousi said in a statement. "Our recently opened Dubai Solutions Center houses the latest sequencing technologies to provide even more support for our customers in the region, helping them deliver genomic precision medicine to an increasing number of patients."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.